Financial Lp Hrt Sells 94,462 Shares of Onconetix (NASDAQ:ONCO) Stock

Onconetix, Inc. (NASDAQ:ONCO) major shareholder Financial Lp Hrt sold 94,462 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $0.75, for a total transaction of $70,846.50. Following the sale, the insider owned 83,359 shares of the company’s stock, valued at $62,519.25. This represents a 53.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, April 21st, Financial Lp Hrt sold 49,710 shares of Onconetix stock. The stock was sold at an average price of $0.69, for a total transaction of $34,299.90.
• On Thursday, April 16th, Financial Lp Hrt sold 53,867 shares of Onconetix stock. The stock was sold at an average price of $0.73, for a total transaction of $39,322.91.
• On Friday, April 17th, Financial Lp Hrt purchased 34,636 shares of Onconetix stock. The shares were purchased at an average price of $0.73 per share, with a total value of $25,284.28.
• On Wednesday, April 15th, Financial Lp Hrt purchased 92,554 shares of Onconetix stock. The shares were purchased at an average price of $0.76 per share, with a total value of $70,341.04.
• On Tuesday, April 14th, Financial Lp Hrt purchased 74,350 shares of Onconetix stock. The shares were purchased at an average price of $0.77 per share, with a total value of $57,249.50.

Onconetix Price Performance

Shares of NASDAQ ONCO opened at $0.73 on Thursday. The company has a 50 day simple moving average of $2.45 and a 200-day simple moving average of $8.45. The company has a market capitalization of $477,371.20, a P/E ratio of 0.00 and a beta of 3.63. Onconetix, Inc. has a 1 year low of $0.66 and a 1 year high of $74.29.

Institutional Trading of Onconetix

An institutional investor recently bought a new position in Onconetix stock. Pacific Capital Wealth Advisors Inc. purchased a new position in shares of Onconetix, Inc. (NASDAQ:ONCO) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned about 0.84% of Onconetix at the end of the most recent reporting period. 23.89% of the stock is currently owned by institutional investors and hedge funds.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.